Introduction
============

Venous thromboembolism (VTE) is a major cause of morbidity and mortality in hospitalized patients ([@b5-cia-3-399]). Risk of VTE associated with surgical procedures is well established, and the benefit of thromboprophylaxis has been clearly demonstrated in surgical settings ([@b23-cia-3-399]). Use of thromboprophylaxis is now a routine practice in patients undergoing surgery. However, recent epidemiological data suggested that the majority of VTE events acquired in hospitals occurred in medical, rather than in surgical patients ([@b48-cia-3-399]). Despite this, prevention of VTE in medical settings has been less extensively studied than in surgical settings. Nevertheless, some good-quality clinical trials have been conducted in the last decade in hospitalized medical patients, and guidelines now exist for these patients. Consensus guidelines published by the American College of Chest Physicians (ACCP) recommend prophylaxis with unfractionated heparin (UFH) or low molecular weight heparin (LMWH) in patients admitted to hospital with congestive heart failure or severe respiratory disease, or who are confined to bed and have one or more additional risk factors, including active cancer, previous VTE, sepsis, acute neurological disease, or inflammatory bowel disease ([@b23-cia-3-399]).

Among medical patients, elderly patients deserve probably more attention than others as regards the risk and the prevention of VTE for many reasons. They are more affected by VTE than younger patients ([@b56-cia-3-399]); the proportion of severe and fatal VTE events is higher in those patients ([@b28-cia-3-399]); the association with other comorbidities is frequent ([@b37-cia-3-399]); diagnosis of pulmonary embolism (PE) is more difficult ([@b42-cia-3-399]; [@b60-cia-3-399]); and finally the risk of bleeding related to anticoagulant treatments is high ([@b49-cia-3-399]), even more due to the high frequency of poly-medication and interaction between used drugs. Therefore, prevention of VTE in this specific population is particularly challenging.

Despite relative high proportion of elderly patients included in the largest recent clinical trials of VTE prevention in medical settings ([@b62-cia-3-399]; [@b45-cia-3-399]; [@b17-cia-3-399]), none were specifically conducted in the elderly population, and only a few other large, well designed, randomized controlled trials have been performed addressing this specific issue ([@b19-cia-3-399]; [@b9-cia-3-399]). Nevertheless some data from these studies are available for elderly patients and are discussed in this review. However, specific concerns, such as bleeding risk or lack of clinical benefit remain, and could explain why the systematic use of prophylaxis in elderly is not well implemented in medical wards ([@b4-cia-3-399]).

After a report of VTE epidemiology and specificities in elderly medical patients, this review gives some practical advice, based on available data, to manage VTE prevention in older patients in medical wards. We also discuss the limits of current data and the challenges to improve the practice and reduce the incidence of VTE in elderly patients.

Venous thromboembolism in elderly medical patients
==================================================

VTE: a disease of elderly patients
----------------------------------

The incidence of VTE increases with age. A population-based study of patients discharged from hospital showed that the incidence of deep venous thrombosis (DVT) increased from 119 per 100,000 patients between 60--69 years old, to 291 per 100,000 patients ≥80 years old ([@b5-cia-3-399]). In France, the global annual incidence of symptomatic VTE was 1.83 per 1000 patients, but reached 10 per 1000 patients aged 75 years or older ([@b56-cia-3-399]). The increased incidence was noted for DVT, but also for PE. Moreover, because of the silent nature of the disease, the incidence of VTE was probably underestimated.

In a post-hoc analysis of MEDENOX study, age \>75 years was found to be an independent risk factor of VTE ([@b3-cia-3-399]), and prevalence of VTE reached 18% in patients ≥75 years old from the placebo group ([@b2-cia-3-399]). Furthermore, elderly patients have often other acquired conditions recognized as risk factors for VTE that contribute to the high incidence of the disease ([@b37-cia-3-399]).

High mortality rate in elderly patients
---------------------------------------

The mortality of acute VTE in elderly is increased: 16% of patients over 80 years died early after the diagnosis of VTE, in comparison with 2% before 40 years, a difference that is confirmed and increased over 3.5 years of follow up ([@b5-cia-3-399]). In the analysis of the RIETE registry, at three months after the venous thromboembolic event, 3.7% of patients aged ≥80 years died of PE compared to 1.1% of patients \<80 years (OR 3.6, 95% CI 2.7--4.7) ([@b49-cia-3-399]).

More severe initial presentation in elderly patients
----------------------------------------------------

In the study by [@b28-cia-3-399], there is a trend of a higher proportion of symptomatic PE in elderly: in patients over 70 years, PE is the manifestation of VTE in 70% of cases, in comparison with 55% of cases under 70 years. This finding is confirmed in the RIETE registry, where patients ≥80 years old were more often enrolled with symptomatic PE ([@b49-cia-3-399]). In this study, patients with VTE aged 80 or over more often weighed \<65 kg, and had a higher rate of chronic lung disease, heart failure and creatinine clearance \<60 mL/min.

Difficulties of diagnosis of PE in elderly patients
---------------------------------------------------

Clinical symptoms and sign of PE are not specific, and PE can be a silent disease as well. Sometimes sudden death is the first clinical manifestation of PE. In autopsy studies, diagnosis of PE was suspected before death in only 10% of patients who died from proven PE ([@b66-cia-3-399]). Diagnosis of PE is particularly difficult in elderly patients because the clinical presentation is less discriminative. The frequency of many cardiopulmonary underlying conditions that may mimic clinical presentation of PE is increased with age, and on the other hand, some classical signs of PE such as hemoptysis, tachycardia, hemidiaphragmatic elevation and pleural effusion were not associated with PE in patients aged 75 years or over ([@b42-cia-3-399]). The characteristics of diagnostic tests for PE are also unfavorably influenced by age ([@b60-cia-3-399]). In a study of 1029 consecutive patients presenting to the emergency department with clinically suspected PE, this diagnosis could be ruled out by a negative D-dimer test in 67% of patients 40 years or under, but in only 10% of patients aged 80 years or older ([@b59-cia-3-399]). Lung scan for PE diagnosis demonstrates a lower performance in elderly due to frequent underlying pulmonary diseases ([@b59-cia-3-399]), and finally, the frequency of renal impairment in elderly patients limits the use of CT-scan.

High bleeding risk in elderly patients
--------------------------------------

The main risk of treatment with anticoagulants, at therapeutic or prophylactic doses, is bleeding. Major data on the risk of bleeding is provided by trials on long term oral anticoagulation. These studies have shown that elderly patients with VTE have a higher risk of bleeding complications ([@b41-cia-3-399]; [@b74-cia-3-399]; [@b47-cia-3-399]). In a prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin, age 65 years or greater was found to be an independent risk factor of major bleeding ([@b12-cia-3-399]). In an analysis from the RIETE registry ([@b49-cia-3-399]), 3.4% of patients ≥80 years old had major bleeding events compared to 2.1% of patients \<80 years. Fatal bleeding occurred in 0.8% in the oldest and 0.4% among patients \<80 years. Recent bleeding, abnormal renal function (creatinine clearance \<60 mL/min), use of corticosteroids or long term therapy with LMWH were independently associated with an increased risk of major bleeding. Other results from the same registry have also shown that major and fatal bleeding events occurred more frequently in acutely ill medical patients than in surgical patients ([@b53-cia-3-399]).

In the case of severe renal insufficiency, UFH can be used, while LMWH are usually contraindicated. However, UFH was also associated with a higher risk of bleeding in the elderly ([@b14-cia-3-399]).

During VTE prophylaxis, results from a meta-analysis of clinical trials conducted in medical settings showed that the incidence of major bleeding was 0.4% in heparin groups, compared to 0.2% in control groups ([@b52-cia-3-399]). In the recent trials, this incidence varied from 0.2% to 1.7% in the treatment groups ([@b62-cia-3-399]; [@b45-cia-3-399]; [@b17-cia-3-399]).

VTE: a complication of medical illness
--------------------------------------

VTE is a major cause of morbidity and mortality in hospitalized patients ([@b5-cia-3-399]). It has been reported that 10% of deaths occurring during hospitalization were related to PE ([@b66-cia-3-399]). Autopsy studies revealed that 70% to 80% of all in-hospital deaths related to PE were not associated with surgical procedures, but occurred in medical patients ([@b25-cia-3-399]; [@b66-cia-3-399]; [@b48-cia-3-399]; [@b7-cia-3-399]). Hospitalization for an acute medical illness was also recognized as an independent factor of VTE associated with about an 8-fold increased relative risk for VTE ([@b27-cia-3-399]). Moreover, the initial presentation and outcomes of VTE were more severe and frequent in patients who developed VTE after an acute medical illness than in patients who developed VTE after a surgical intervention ([@b53-cia-3-399]).

Before the publication of the more recent large clinical trials, the incidences of DVT (including asymptomatic DVT) and clinical PE in medical patients not receiving prophylaxis were respectively estimated at about 19% and 1% ([@b52-cia-3-399]). Results from recent large clinical trials for VTE incidence rates in placebo groups were: 15% in the MEDENOX study ([@b62-cia-3-399]), 5% in PREVENT study ([@b45-cia-3-399]), and 11% in ARTEMIS study ([@b17-cia-3-399]). Differences in asymptomatic outcomes definition (proximal alone or distal and proximal DVT), and methods to measure these outcomes (venography or compression ultrasonography) could explain this relatively wide interval for incidence rates.

Among hospitalized patients, elderly medical patients are probably the most affected by VTE. As a result, the proportion of preventable events by an effective thromboprophylaxis is expected to be high in this population. Moreover, because of VTE specificities in elderly (high mortality rate, severe initial presentation, difficult diagnosis of PE and high risk of major bleeding with anticoagulant drugs at therapeutic doses), primary prophylaxis with the use of an effective and safe intervention appears to be the best approach to VTE management.

Management of thromboprophylaxis in elderly medical patients
============================================================

Do all hospitalized elderly medical patients need a thromboprophylaxis?
-----------------------------------------------------------------------

The first question in front of a newly admitted elderly patient is whether they will require prevention against VTE; in other words, we have to systematically assess the individual risk of venous thrombosis, and select the patients for whom thromboprohylaxis would be helpful.

This assessment, and therefore the decision of prescribing a prophylaxis, should be based on the presence or absence of specific risk factors ([Table 1](#t1-cia-3-399){ref-type="table"}). Previous studies have identified a number of risk factors for VTE in medical patients ([@b5-cia-3-399]; [@b65-cia-3-399]; [@b28-cia-3-399]; [@b26-cia-3-399]; [@b6-cia-3-399]). Many of these factors are frequent in elderly hospitalized patients, alone or combined and generally cumulative ([@b37-cia-3-399]; [@b61-cia-3-399]). However, individual risk assessment in medical settings can be problematic in practice.

In clinical trials on thromboprophylaxis in medical settings, eligibility criteria included most of the various risk factors ([Table 2](#t2-cia-3-399){ref-type="table"}) but they differ between studies and cannot be easily repeated ([@b62-cia-3-399]; [@b45-cia-3-399]; [@b17-cia-3-399]). Thromboprophylaxis has been studied specifically in some medical conditions such as stroke ([@b34-cia-3-399]; [@b68-cia-3-399]), myocardial infarction ([@b58-cia-3-399]) or cancer ([@b46-cia-3-399]; [@b33-cia-3-399]). Instead of providing clarification, the decision of whom and how to treat may become more difficult as a result.

Nevertheless, assessment of the risk of VTE is probably easier for elderly than for other medical patients. Because age over 75 years is an independent risk factor of VTE in medically ill patients ([@b3-cia-3-399]), the presence of only one additional acute medical condition is required to consider thromboprophylaxis for these patients, using for example the risk assessment model developed by [@b16-cia-3-399]. A thromboprophylaxis should be proposed if the hospitalization is motivated by one of these following conditions: acute myocardial infarction, acute heart failure, active cancer requiring therapy, acute infectious disease, respiratory disease, acute rheumatologic disease, ischemic stroke, paraplegia, and inflammatory disorder with immobility or inflammatory bowel disease.

In conclusion, elderly medical patients should receive a thromboprophylaxis if an acute medical illness is the leading cause of hospitalization.

Which prophylaxis should be used?
---------------------------------

Among thromboprophylactic methods, anticoagulant treatments with UFH or LMWH are the regimens of choice, but they share main contraindications: untreated hemophilia and other hemorrhagic disorder, active bleeding or perceived bleeding risk (peptic ulcer, recent cerebral hemorrhage, severe hypertension, and severe liver disease), thrombocytopenia with platelets \<60 × 10^9^/L, a history of heparin-induced thrombocytopenia, and hypersensitivity to heparin.

Because of its principally renal route of elimination, LMWH, even at prophylactic doses, must be used with caution in patients with renal failure. When creatinine clearance is less than 30 mL/min, UFH may be preferred.

Before prescribing an anticoagulant regimen, we need to check systematically the potential contraindications: baseline risk of bleeding, platelets count and renal function. In the event that there is a contraindication to pharmacological thromboprophylaxis, consider nonpharmacological treatments. Nonpharmacological strategies include graduated compression stockings, intermittent pneumatic compression, leg elevation, and early mobilization. No randomized clinical trials have evaluated mechanical methods of prophylaxis in general medical patients. These measures should be considered as alternative methods when contraindications to anticoagulants exist ([@b23-cia-3-399]). If there is no contraindication to pharmacological treatments, use LMWH or UFH.

### Prophylactic treatment versus placebo ([Table 3](#t3-cia-3-399){ref-type="table"})

Seven trials comparing a prophylactic heparin treatment to a control (15,095 patients) in medical patients were selected in the meta-analysis by [@b52-cia-3-399]. Four studies evaluated UFH at 10000 IU or 15000 IU daily ([@b8-cia-3-399]; [@b13-cia-3-399]; [@b31-cia-3-399]; [@b22-cia-3-399]) and three studies evaluated a LMWH (enoxaparin or nadroparin) ([@b19-cia-3-399]; [@b9-cia-3-399]; [@b21-cia-3-399]). A significant decrease in DVT and in clinical PE were observed with heparins as compared to control (risk reductions of 56% and 58% respectively, p \< 0.001 in both cases), without significant difference in the incidence of major bleedings or deaths.

In the MEDENOX study, patients of 75 years or older accounted for more than half of acute ill medical patients included in the trial ([@b62-cia-3-399]). A post-hoc analysis was performed in the subgroup of older patients ([@b2-cia-3-399]). Those who received 40 mg enoxaparin had a 78% reduction in VTE when compared with placebo (absolute risk reduction 14.4%; relative risk \[RR\] 0.22; 95% CI, 0.09--0.51). The incidence of adverse effects, including hemorrhages, did not differ significantly between the placebo group and either enoxaparin group in the primary analysis, but no data were reported for the subgroup of elderly patients.

The PREVENT trial included medical patients randomized to receive dalteparin, 5000 IU once daily, or placebo ([@b45-cia-3-399]). In the subgroup of patients 75 years or older, who represented one third of the population included in the trial, the primary end point was reported in 4.2% with dalteparin and 8.0% with placebo (RR 0.52; 95% CI, 0.31--0.87) ([@b39-cia-3-399]). Dalteparin was not associated with a significant increase in major hemorrhage (1.1% vs 0.7%; p = 0.12).

The ARTEMIS study was designed to evaluate the efficacy and safety of the anticoagulant fondaparinux in older acute medical inpatients at moderate to high risk of VTE ([@b17-cia-3-399]). To our knowledge, no specific data concerning the subgroup of elderly patients were already published.

Two double-blind randomized studies evaluated thromboprophylaxis without systematic assessment of asymptomatic DVT at the end of the treatment period ([@b9-cia-3-399]; [@b44-cia-3-399]). In the first study, nadroparin did not have a significant effect on mortality and the study provided no data suggesting that nadroparin may reduce the incidence of thromboembolic events in patients hospitalized for an acute medical disease ([@b9-cia-3-399]; [@b50-cia-3-399]). In the second study, the primary outcome was the total mortality at 90 days after randomization, but authors reported also the number of readmission due to objectively proven symptomatic venous thromboembolic events occurring within 90 days of randomization ([@b44-cia-3-399]). Overall mortality and occurrence of clinical thromboembolic events did not differ between enoxaparin and placebo.

### Comparison of prophylactic anticoagulant regimens

A meta-analysis of eight trials comparing UFH and LMWHs in medical patients found no significant differences between the two treatment groups on the incidence of DVT, clinical PE or mortality ([@b52-cia-3-399]). However, LMWH seemed to be safer than UFH by reducing the risk of major hemorrhage (RR 52%, p = 0.049).

In the recent meta-analysis by [@b73-cia-3-399] that included studies of patients with acute ischemic stroke, LMWH was associated with a reduced risk of DVT (RR, 0.68; 95% CI, 0.52--0.88) and injection site hematoma (RR, 0.47; 95% CI, 0.36--0.62) compared with UFH. No statistically significant differences were observed between the two treatments with respect to PE, mortality, total bleeding, and major or minor bleeding.

Enoxaparin 20 mg once daily and UFH 5000 IU twice daily were considered equivalent in terms of efficacy in patients aged 65 years or more (mean age 83 years) and no significant difference was found in terms of safety (Bergman and Neuhart 1996). However, MEDENOX study suggested that enoxaparin at 20 mg was ineffective for preventing VTE in acutely ill medical patients compared to placebo ([@b62-cia-3-399]).

Enoxaparin 40 mg subcutaneously once daily was shown to be as effective as UFH 5000 IU three times daily in the PRIME and PRINCE studies ([@b43-cia-3-399]; [@b36-cia-3-399]). The PRIME study included various medical patients (mean age 74 years), and the PRINCE study included patients (mean age 70 years) with severe respiratory disease or heart failure.

The recent PREVAIL study was designed to assess the efficacy and safety of enoxaparin versus UFH for the prevention of VTE in patients with acute ischemic stroke ([@b68-cia-3-399]). The mean age of included patients was 66 years, and 25% of patients were older than 75 years. More than 90% of patients received a concomitant medication by an antiplatelet drug. Enoxaparin was significantly more effective than UFH for the prevention of VTE in patients with acute ischemic stroke (RR 0.57, 95% CI 0.44--0.76), without significant difference in terms of bleedings (8% vs 8%; p = 0.83) or symptomatic intracranial hemorrhage (1% vs 1%; p = 0.55).

No studies have directly compared different modalities of UFH administration. However, a recent meta-analysis comparing UFH given twice daily or 3 times daily from 12 studies found no difference in the overall rate (per 1000 patient-days) of VTE (twice daily: 5.4 vs 3 times daily: 3.5; p = 0.87), but an increased risk of major bleedings with three times daily heparin (twice daily: 0.35 vs 3 times daily: 0.96; p \< 0.001) ([@b35-cia-3-399]).

In regards to the risk of heparin-induced thrombocytopenia (HIT) that should be considered when providing patients with thromboprophylaxis, LWMHs appeared safer than UFH in surgical patients ([@b72-cia-3-399]). However, in the recent meta-analysis by [@b73-cia-3-399], no statistically significant differences were observed between UFH and LMWH with respect to thrombocytopenia (RR, 0.25; 95% CI, 0.05--1.16).

### Cost effectiveness analyses

Several studies conducted in different countries have evaluated the cost effectiveness of LMWH relative to UFH or to no pharmacological prophylaxis for DVT prevention in medical inpatients ([@b40-cia-3-399]; [@b55-cia-3-399]; McCarry et al 2004; [@b67-cia-3-399]; [@b69-cia-3-399]). Regardless of some methodological differences, they conclude that, despite higher acquisition costs, LMWHs for thromboprophylaxis in medical patients resulted in savings compared to no pharmacological prophylaxis and were associated with lower costs or at least neutral cost compared with UFH.

To conclude, based on the results of the clinical trials presented above, elderly patients hospitalized for an acute medical illness should receive a prophylactic anticoagulant treatment unless there is a contraindication. LMWHs, enoxaparin at the dose of 40 mg and dalteparin at the dose of 5000 IU, are effective and safe to prevent VTE in elderly patients. Compared to UFH, they are more convenient, requiring only one subcutaneous injection daily. They are associated with a lower risk of heparin-induced thrombocytopenia, and finally are equal or superior in cost effectiveness analyses. In case of severe alteration of renal function however, the safety of LMWHs is uncertain and UFH should be considered. More data are needed to recommend the use of fondaparinux as a routine treatment in elderly patients. In case of contraindication to heparins, graduated stockings or intermittent pneumatic compression should be used.

### For how long should the treatment be given?

In the main randomized trials, prophylactic treatment was given for 1 to 2 weeks. While no specific recommendations exist regarding the duration of anticoagulant treatment, treatment would therefore not exceed this length. However, some elements could be discussed in favor of duration extension in medical patients, and especially in elderly medical patients.

First, it is likely that the thrombotic process has already started in some patients before their admission to hospital. In a study evaluating the prevalence of VTE in medical patients hospitalized for another reason than VTE, asymptomatic VTE at admission was diagnosed in 17.8% of patients over 80 years ([@b57-cia-3-399]).

Second, in the MEDENOX, PREVENT and ARTEMIS studies, additional symptomatic VTE events and fatal PE occurred after discontinuation of prophylaxis during the follow up period in the treatment groups ([@b62-cia-3-399]; [@b45-cia-3-399]; [@b17-cia-3-399]).

Third, extension of prophylaxis duration was shown to be effective in other settings. In major orthopedic surgery, a meta-analysis of randomized trials confirmed that prolonged prophylaxis with LWMH for one month postoperatively, compared with the standard practice of prescribing prophylaxis for 7--10 days, reduced the relative risk of all DVT events by 59% (p \< 0.001), and reduced the risk of symptomatic VTE by 64% (p \< 0.001), without increasing bleeding complications ([@b29-cia-3-399]). Benefit of prolonged prophylaxis to 25--31 days was also demonstrated in patients with active cancer who were undergoing surgery (Berqvist et al 2002).

The Extended Clinical Prophylaxis in Acutely III Medical Patients (EXCLAIM) trial was designed to demonstrate the superiority of extended-duration prophylaxis with enoxaparin (28 ± 4 days) compared with the standard regimen of enoxaparin (10 ± 4 days) for prevention of VTE in acutely ill medical patients with recent reduced mobility ([@b30-cia-3-399]). Mean age of included patients was 70 years, with more than 40% of patients being 75 years or older. Extended-duration prophylaxis with enoxaparin was more effective than standard regimen of enoxaparin on the primary efficacy endpoint (asymptomatic DVT detected by ultrasonography, symptomatic DVT, symptomatic PE, fatal PE) (2.8% vs 4.9%, RR 0.56, 95% CI 0.39--0.80). However, major hemorrhagic complications occurred significantly more frequently with the extended-duration prophylaxis (0.60% vs 0.15%, RR 4.03; 95% CI 1.14--14.3) ([@b30-cia-3-399]).

One or two weeks is the common duration of prophylactic treatment with LMWH or UFH. Extension of prophylaxis duration to one month appeared to be more effective than standard duration but was also associated with an excess of major bleedings. Awaiting further analyses of the EXCLAIM study, extended-duration prophylaxis in medical patients should be discussed on a case-by-case basis.

Is a monitoring of pharmacological prophylaxis required?
--------------------------------------------------------

The highest risk of anticoagulant prophylaxis is bleeding. Even if major bleedings are less frequent with prophylactic than with therapeutic doses, physicians should be aware of this risk, and should observe their patients regularly by clinical examination for all potential bleedings. Moreover, underlying conditions or associated treatments could change during hospitalization, and this could increase the bleeding risk associated with thromboprophylaxis. A regular reassessment of the benefit and risk of thromboprophylaxis decided on admission should be performed taking into account the potential modifications since admission, for example, the modifications of renal function or the presence of a newly diagnosed contraindication. However, no specific biological monitoring is needed to evaluate the anticoagulant activity of UFH or LMWH at prophylactic doses.

Less frequent, but often fatal, is the potential development of HIT. Even if HIT appeared to be less frequently observed with LMWH than with UFH, a monitoring of platelets count is required at least twice weekly for all heparins during the treatment period ([@b71-cia-3-399]).

Regular assessment of bleeding risk associated with thromboprophylaxis should be performed, taking into account the potential changes in underlying conditions and associated treatments. A monitoring of platelets count is required for UFH as well as for LMWH.

A proposition of management of thromboprophylaxis in elderly medical patients is resumed in [Figure 1](#f1-cia-3-399){ref-type="fig"}.

Why is thromboprophylaxis in the elderly not better adopted in clinical practice?
=================================================================================

The gap between theory and practice
-----------------------------------

Despite available data, and recommendations for VTE prevention in medical patients, underuse or misuse of thromboprophylaxis remains a problem. A case series study showed that among 208 patients who developed acute VTE during hospitalization in medical wards, only 48% had received VTE prophylaxis ([@b24-cia-3-399]). Recently, the Canadian CURVE study aimed to determine the proportion of hospitalized, acutely ill medical patients who were eligible to receive thromboprophylaxis, and to evaluate the frequency, determinants and appropriateness of its use ([@b32-cia-3-399]). Following ACCP guidelines, authors found that of the 1894 medical hospitalized patients who were eligible for study inclusion, 90% should receive a thromboprophylaxis. However, only 23% received a prophylaxis, and only 16% received an appropriate thromboprophylaxis.

Use of prophylaxis in elderly medical patients is unknown, but thought to be as low as in general medical patients. Nevertheless, in CURVE study, age was not found as a determinant of thromboprophylaxis use ([@b32-cia-3-399]), and in IMPROVE study, prophylaxis with LMWH or UFH was more likely to be used if patients were aged ≥85 years ([@b70-cia-3-399]). In the study by [@b15-cia-3-399], patients treated by thromboprophylaxis were older than those without prophylaxis. The rate of patients needing thromboprophylaxis and not receiving it was lower for older patients (\>75 years) than for younger patients. However, the rate of patients not needing thromboprophylaxis and receiving it was higher for older patients than for younger patients.

Explaining the gap
------------------

The gap between theory and practice for the use of thromboprophylaxis could be explained by many reasons. Heterogeneity of clinical studies, selected populations, concern about bleedings, and the lack of a clear clinical benefit are some of these reasons.

### Heterogeneity of clinical trials

Clinical trials highlighted the benefit of pharmacological treatment for VTE prevention in medical patients ([@b62-cia-3-399]; [@b45-cia-3-399]; [@b17-cia-3-399]). However, the different rates of VTE incidence from 4.8% to 14.9% in the placebo groups suggested disparities between studies. This may reflect the heterogeneous medical conditions of the different populations studied, as well as differences in the endpoints and outcomes measure. In fact, any study could be directly compared to another. When two studies shared the same inclusion criteria, treatments and/or primary end points and/or modalities to measure the outcomes were different.

As presented in [Table 2](#t2-cia-3-399){ref-type="table"}, eligibility criteria of clinical trials, and the resulting validated indications of thromboprophylaxis evaluated in these trials are various and different between studies. Compared to surgical settings, there is a lack of legibility of eligibility criteria for the use of thromboprophylaxis in medical settings. This complexity is discouraging and could explain its underuse.

Homogenization of outcomes definition, outcomes measure and simplification of eligibility criteria are probably needed for further trials. This may help to clarify the recommendations and to improve the practice.

### Selected medical populations, and probably high selected elderly populations

Inclusion and exclusion criteria of clinical trials lead to selected populations, and results should be interpreted with caution before being extrapolated to a larger population. Taking into account the high proportion of patients hospitalized in medical wards, the number of patients included in the clinical trials was low. In IMPROVE, only 13%--19% of all patients would have been eligible for inclusion in MEDENOX, PREVENT, or ARTEMIS studies ([@b4-cia-3-399]). This problem can be also illustrated by the results of the CURVE study ([@b32-cia-3-399]). Over the 3-week study period, in 29 hospitals across Canada, 1702 medical patients had an indication of thromboprophylaxis. This number is higher than the number of included patients in MEDENOX study over 18 months in 60 centers from nine countries.

Furthermore, many patients who were usually hospitalized in geriatric units, were unable to sign a written informed consent, presented alteration of renal function or low weight were excluded from these trials. Renal insufficiency and low weight, two frequent conditions in elderly patients and associated with higher risk of bleeding ([@b49-cia-3-399]), were often exclusion criteria. Therefore, selection of a population with low risk of bleeding in clinical trials was likely and concern about bleeding with thromboprophylaxis could be a reason of its underuse in elderly patients. Moreover, as an informed consent is required, patients need to understand and approve the enrolment in the study. Unfortunately, only few patients among the oldest are able to give such consent, because of impairment of cognitive functions, or too severe weakness to be able to participate.

Despite findings of clinical trials suggesting that thromboprophylaxis is effective and safe in the elderly patients, few trials enrolled specifically geriatric patients. Additionally, elderly patients were probably highly selected and therefore not representative of overall elderly medical patients.

### Lack of evident clinical benefit?

Only few trials were conducted using symptomatic VTE and/or mortality as the primary end point. In the majority of clinical trials, the primary end point was a combined outcome including symptomatic VTE (DVT and/or fatal and non fatal PE) and asymptomatic DVT systematically assessed at the end of the treatment period. Asymptomatic DVT, however, were the great majority of events detected during the studies. In medical patients, there is a lack of evidence that prophylaxis prevents clinically important outcomes, such as PE, which has been shown in surgical patients ([@b18-cia-3-399]). Therefore, some could argue about the clinical relevance of the results from trials conducted in medical settings.

A recent meta-analysis aimed to evaluate the effects of anticoagulant prophylaxis in reducing clinically important VTE outcomes in hospitalized medical patients ([@b20-cia-3-399]). Prophylaxis (with UFH, LMWH or fondaparinux) was associated with a significant reduction of any PE (RR: 0.43, CI, 0.26--0.71) and fatal PE (RR: 0.38, CI, 0.21--0.69), a nonsignificant reduction in symptomatic DVT and a nonsignificant increase in major bleeding. Anticoagulant prophylaxis had no effect on all-cause mortality. However, the main limitation of this analysis is that the results concerned only the treatment period. How are they maintained after the treatment has been stopped (which is really the relevant question) is unknown.

The benefit of prophylaxis in medical patients is uncertain for clinical nonfatal VTE events, and no benefit on overall mortality was demonstrated. How these results are relevant for elderly population remains to be determined.

Challenges to improve the practice
----------------------------------

As life expectancy is increasing in developed countries, incidence of VTE is also expected to increase. How to prevent this potential fatal disease will arise as a major public health problem for the next decades. According to the Agency for Healthcare Research and Quality in the United States, prevention of VTE in adult patients in hospital was the main challenge to patient safety in 2001 ([@b1-cia-3-399]).

Therefore, many efforts have to be done to improve thromboprophylaxis particularly in the elderly. Determining the optimal strategy of prevention is essential and further trials conducted specifically in the elderly nonselected patients and evaluating the benefit-risk ratio of thromboprophylaxis are needed. However, available results suggested that some prophylactic treatments were effective and safe even in the older patients. These treatments should be more used in practice following the available guidelines. But the use of such treatments in the "real life" and for patients that would have not been included in the clinical trials must be evaluated. Reducing the gap between theory and practice shown by many studies should reduce the number of patients exposed to high risk of thrombosis and not receiving effective prevention.

To improve practice, some suggestions should be proposed in all hospitals:

-   Results of epidemiologic studies highlighted the importance of VTE in in-hospital morbi-mortality should be largely taught. This would reduce the lack of awareness that VTE is a real public health problem among all practitioners.

-   Models of assessment of the VTE risk should be validated and more used. Assessment of the risk of VTE for all medical patients is the first recommendation of current guidelines ([@b54-cia-3-399]; [@b23-cia-3-399]). However, assessing the individual risk of VTE in medical settings is difficult. Models to assess this risk have been developed to assist the physicians to determine if thromboprophylaxis is warranted or not ([@b64-cia-3-399], [@b63-cia-3-399]; [@b16-cia-3-399]). But these models have not been validated in specifically designed prospective clinical trials, they are less structured than in surgical settings and are not conceived for elderly patients. Nevertheless, systematic assessment of VTE risk at admission has been shown to improve the prophylaxis practice in an original initiative conducted in Brigham and Women's Hospital in Boston ([@b38-cia-3-399]). A computer program linked to the patient database was developed to identify consecutive hospitalized patients at risk for DVT in the absence of prophylaxis. Eligible patients were randomly assigned to an intervention group, in which the responsible physician was alerted to a patient's risk of DVT, and to a control group, in which no alert was issued. The computer alert reduced the risk of VTE at 90 days by 41% (HR, 0.59; 95% CI, 0.43--0.81). These encouraging findings suggested that alerting physicians to the individual risk of VTE could contribute to improve the rate of clinical outcomes.

-   Regular updates on prevention of VTE in medical settings should also be proposed in Continuing Medical Education programs. On these occasions, last data and last recommendations of experts could be presented and discussed.

Finally, further studies are needed to determine the place of the new anticoagulant drugs, such as direct Factor Xa inhibitors or antithrombin inhibitors, in the prevention of VTE in medical settings. Besides their effectiveness and safety demonstrated in surgical settings, their pharmacokinetic properties (that allow one oral daily dose) provide other advantages that should be useful in daily practice.

Conclusions
===========

Elderly patients are the most concerned by VTE, and development of optimal thromboprophylaxis strategies should be a priority in this population. Further clinical trials evaluating efficacy and risk of thromboprophylactic methods, including new anticoagulant drugs, are needed for elderly patients. Awaiting such trials, and despite some limitations, available data from existing clinical trials conducted in hospitalized medical patients supported a good benefit-risk ratio of different thromboprophylaxis modalities in geriatric patients. Nevertheless, in practice, the balance between expected benefit and risk of prophylactic anticoagulation should be carefully assessed for each individual elderly patient taking into account the specific risk of VTE in older patients and the risk of anticoagulant related bleeding probably underestimated in clinical trials. Risk assessment models developed for overall medical patients are useful tools to improve the use of thromboprophylaxis even in elderly patients, but remain to be evaluated in this specific population.
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###### 

Risk factors of venous thromboembolism in medical patients

  Permanent underlying risk conditions   Acute medical conditions               Iatrogenic risk factors
  -------------------------------------- -------------------------------------- --------------------------------------
  Advanced age (\>75 years)              Heart failure                          Hormone replacement therapy
  History of VTE                         Severe respiratory diseases            Hospital or nursing home confinement
  Varicose veins                         Acute infectious diseases              
  Obesity                                Malignancy                             Chemotherapy
  Malignancy                             Stroke                                 Central venous catheter
  Thrombophilia                          Prolonged immobilization (\>3 years)   
                                         Myocardial infarction                  

###### 

Eligibility criteria in MEDENOX, PREVENT, and ARTEMIS clinical trials

  MEDENOX                                                                                                                                                                                                                                                                                                                              PREVENT                                                                                                                                                                                                                                                              ARTEMIS
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Age ≥ 40 years                                                                                                                                                                                                                                                                                                                       Age ≥ 40 years                                                                                                                                                                                                                                                       Age ≥ 60 years
  -- Expected hospital stay ≥6 days-- Recent immobilization (≤3 days)-- Congestive heart failure (NYHA III/IV) or acute respiratory failure, or one medical condition if associated with at least one additional risk factor of VTE.                                                                                                   -- Expected hospital stay ≥4 days-- Recent immobilization (≤3 days)-- Congestive heart failure (NYHA III/IV) or acute respiratory failure or one medical condition if associated with at least one additional risk factor of VTE.                                    -- Expected bed rest ≥4 days-- Congestive heart failure (NYHA III/IV) or acute respiratory illness in the presence of chronic lung disease, or clinically diagnosed acute infections or inflammatory disorders such as arthritis, connective tissue diseases, or inflammatory bowel disease.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  Medical conditions were: acute infection without septic shock; acute rheumatic disorders, including acute lumbar pain or sciatica or vertebral compression (caused by osteoporosis or a tumor), acute arthritis of the legs, or an acute episode of rheumatoid arthritis in the legs, or an episode of inflammatory bowel disease.   Medical conditions were: infection without septic shock, acute rheumatologic disorders, or inflammatory bowel disease                                                                                                                                                No other risk factor required
  Additional risk factors of VTE were: age ≥75 years, cancer, previous VTE, obesity, varicose veins, hormone therapy (antiandrogen or estrogen, except for postmenopausal hormone-replacement therapy), and chronic heart or respiratory failure                                                                                       Additional risk factors of VTE were: age ≥75 years, cancer, previous VTE, obesity, varicose veins and/or chronic venous insufficiency, hormone replacement therapy, history of chronic heart failure, chronic respiratory failure, or myeloproliferative syndrome.   

###### 

Double-blind randomized clinical trials evaluating thromboprophylaxis versus placebo in various medical patients

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author, study, year                  Treatment                                       Treatment duration                                       Eligible age (mean age) in years   Number of patients   Primary outcome                                                                                                                                                                Results: Efficacy of thromboprophylaxis vs placebo
  ------------------------------------ ----------------------------------------------- -------------------------------------------------------- ---------------------------------- -------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------
  [@b19-cia-3-399]                     Enoxaparin 60 mg sc od                          Until discharge or 10 days                               ≥65 (80)                           270                  DVT diagnosed by ^125^I fibrinogen scanning                                                                                                                                    DVT: 3% in enoxaparin group vs 9.1% in placebo group (p = 0.03)

  [@b9-cia-3-399] ([@b50-cia-3-399])   Nadroparin 0.3 mL sc od                         For up to 21 days                                        ≥40 (76)                           2474                 Total mortality at the end of the study time, defined as 21 days or death.                                                                                                     Mortality: 10.1% in nadroparin group vs 10.3% in placebo group (NS)

  [@b62-cia-3-399]                     Enoxaparin 40 mg sc od Enoxaparin 20 mg sc od   For 14 days (mean duration: 7 days) Follow-up 110 days   ≥40 (73)                           1102                 VTE defined as asymptomatic DVT detected by bilateral venography or ultrasonography or symptomatic DVT or documented PE                                                        VTE: 15.0% in enoxaparin 20 mg group vs 14.9% in placebo group (NS)\
                                                                                                                                                                                                                                                                                                                                                                                       VTE: 5.5% in enoxaparin 40 mg group vs 14.9% in placebo group (p \< 0.001)

  [@b45-cia-3-399]                     Dalteparin 5000 IU sc od                        For 14 days Follow-up 90 days                            ≥40 (68.5)                         3706                 VTE defined as symptom- atic DVT (proximal or distal), fatal or symptom- atic nonfatal PE, sudden death, and asymptomatic proximal DVT detected by ultrasonography at day 21   VTE: 2.8% in dalte- parin group vs 5.0% in placebo group (p = 0.0015)

  [@b17-cia-3-399]                     Fondaparinux 2.5 mg sc od                       For 14 days (median of 7 days) Follow-up 32 days         ≥60 (75)                           849                  VTE defined as symptomatic DVT or PE or asymptomatic DVT detected by bilateral venography                                                                                      VTE: 5.6% in fondaparinux group vs 10.5% in placebo group (p = 0.029)

  [@b44-cia-3-399]                     Enoxaparin 40 mg sc od                          Until discharge Follow-up 90 days                        ≥60 (71.5)                         280                  Total mortality at 90 days                                                                                                                                                     Mortality: 9.3% in enoxaparin group vs 10% in placebo group (NS)
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
